The delta-selective PI3K blockers idelalisib and IC488743 have demonstrated cytotoxicity in murine myeloma models [83] while copanlisib (BAY 80-6946), which is selective for the alpha isoform, has been shown to be effective against four different MM cell lines [92]. This evidence concerns the gene PIK3CG and Miyoshi myopathy.